Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $27 to $26.
Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $27 to $26.